Considering that AD is a complex disease with a strong component of type 2 immune response and severe itch-related neuroinflammation [1, 5], which contribute to the clinical presentation of epidermal hyperplasia and the molecular regulation of p63 [49, 50, 72, 73], it would be of great interest to further investigate the impact of modulating NLRP10 in a disease-relevant context. This evidence concerns the gene NLRP10 and Alzheimer disease.